Integra Lifesciences Holdings Corp (NASDAQ:IART) – Research analysts at Jefferies Group boosted their Q2 2018 earnings per share estimates for shares of Integra Lifesciences in a research report issued to clients and investors on Tuesday, according to Zacks Investment Research. Jefferies Group analyst R. Denhoy now expects that the life sciences company will post earnings per share of $0.58 for the quarter, up from their prior estimate of $0.57. Jefferies Group has a “Buy” rating and a $63.00 price objective on the stock. Jefferies Group also issued estimates for Integra Lifesciences’ Q2 2019 earnings at $0.68 EPS, Q4 2019 earnings at $0.75 EPS, FY2020 earnings at $3.08 EPS, FY2021 earnings at $3.53 EPS and FY2022 earnings at $4.02 EPS.
IART has been the topic of several other reports. BidaskClub downgraded shares of Integra Lifesciences from a “sell” rating to a “strong sell” rating in a research note on Friday, January 5th. Oppenheimer reissued a “buy” rating on shares of Integra Lifesciences in a research note on Thursday, January 11th. Barclays reaffirmed a “hold” rating and issued a $53.00 price target on shares of Integra Lifesciences in a research note on Tuesday, January 9th. UBS downgraded shares of Integra Lifesciences to a “market perform” rating in a research note on Tuesday, January 2nd. Finally, Raymond James Financial reaffirmed a “market perform” rating and issued a $55.00 price target on shares of Integra Lifesciences in a research note on Tuesday, January 2nd. Ten equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Integra Lifesciences presently has a consensus rating of “Hold” and an average target price of $54.90.
Shares of Integra Lifesciences stock traded down $1.60 during trading hours on Thursday, reaching $54.15. 505,529 shares of the company’s stock traded hands, compared to its average volume of 524,348. The company has a debt-to-equity ratio of 1.85, a quick ratio of 1.51 and a current ratio of 2.36. Integra Lifesciences has a 52 week low of $40.51 and a 52 week high of $58.17. The firm has a market cap of $4,466.32, a P/E ratio of 66.04, a P/E/G ratio of 1.75 and a beta of 0.65.
Integra Lifesciences (NASDAQ:IART) last announced its earnings results on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.08. Integra Lifesciences had a net margin of 5.45% and a return on equity of 16.94%. The company had revenue of $368.60 million for the quarter, compared to the consensus estimate of $362.64 million. During the same period in the previous year, the business earned $0.52 EPS. The company’s revenue was up 44.2% on a year-over-year basis.
In related news, VP Joseph Vinhais sold 6,800 shares of the company’s stock in a transaction on Friday, March 9th. The shares were sold at an average price of $54.13, for a total value of $368,084.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Glenn Coleman sold 8,769 shares of the company’s stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $56.10, for a total transaction of $491,940.90. The disclosure for this sale can be found here. Insiders sold 79,765 shares of company stock valued at $4,314,208 over the last quarter. 21.50% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of the stock. Xact Kapitalforvaltning AB bought a new stake in Integra Lifesciences in the fourth quarter worth $311,000. Segall Bryant & Hamill LLC boosted its holdings in Integra Lifesciences by 12.0% during the fourth quarter. Segall Bryant & Hamill LLC now owns 125,992 shares of the life sciences company’s stock valued at $6,030,000 after acquiring an additional 13,472 shares during the period. MetLife Investment Advisors LLC bought a new stake in shares of Integra Lifesciences in the fourth quarter valued at about $1,390,000. Gotham Asset Management LLC bought a new stake in shares of Integra Lifesciences in the fourth quarter valued at about $3,453,000. Finally, Meadow Creek Investment Management LLC lifted its stake in shares of Integra Lifesciences by 23.9% in the fourth quarter. Meadow Creek Investment Management LLC now owns 8,568 shares of the life sciences company’s stock valued at $410,000 after buying an additional 1,652 shares during the period. Hedge funds and other institutional investors own 90.92% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Q2 2018 Earnings Forecast for Integra Lifesciences Holdings Corp Issued By Jefferies Group (IART)” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://ledgergazette.com/2018/03/23/q2-2018-earnings-forecast-for-integra-lifesciences-holdings-corp-issued-by-jefferies-group-iart.html.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com